ABSTRACT
Background Understanding the intercontinental and regional cancer burden attributable to modifiable risk factors is crucial for developing effective prevention strategies. Using GBD 2021 data, this study aims to identify disparities in cancer burden, predict future trends across different continents, and inform targeted interventions.
Methods This study utilized the GBD 2021 framework to comprehensively assess the cancer burden across four world regions, with a focus on age-standardized incidence rates (ASIR), age-standardized mortality rates (ASMR), and disability-adjusted life years (DALYs). We systematically analyzed cancer-related risk factors using associations extracted from the GBD database. Through the application of average annual percent change (AAPC) and the Bayesian age-period-cohort (BAPC) model, we forecasted the cancer burden in each region from 2022 to 2035.
Findings In 2021, cancer incidence and mortality rates varied widely across continents. The Americas led with an incidence of 1,633.49 per 100,000 and a mortality rate of 116.097, while Europe showed 950.248 and 132.578, respectively. Asia reported 636.893 incidence and 112.329 mortality, and Africa recorded the lowest rates at 332.175 and 98.594. High mortality is associated with elevated DALYs, notably in Europe with 3,284.53 DALYs per 100,000, reflecting the highest cancer burden. In high-income regions, lifestyle-related cancers-linked to smoking, colorectal, and breast cancers-prevail, while low-income areas, particularly sub-Saharan Africa, experience infection-driven cancers like cervical cancer. Younger females under 35 bear a higher cancer burden than males, but after 70, the trend reverses significantly, with men having higher mortality across all ages. Smoking is the leading mortality risk in the Americas, Europe, and Asia, while unsafe sex dominates in Africa, correlating with high cervical cancer incidence. From 1990 to 2021, high BMI and blood glucose have surged as cancer risk factors, driven by obesity and metabolic diseases. By 2035, projections indicate incidence will increase to 1,779.6 per 100,000 in the Americas, with stable mortality at 98.97, while Asia, Africa, and Europe are expected to see moderate incidence and mortality shifts, reflecting regional disparities in cancer prevention and management strategies.
Interpretation This study reveals pronounced global disparities in cancer burden, shaped by economic development, healthcare access, and lifestyle factors. High-income regions, like North America and Europe, show high incidence but lower mortality rates due to robust screening and preventive measures. Conversely, low-income regions, especially sub-Saharan Africa, experience high mortality from preventable cancers, highlighting critical healthcare gaps. Gender analysis shows women have higher incidence due to screening, while men face higher mortality risks. Projected increases in incidence globally underscore the urgency for tailored cancer control strategies, focusing on prevention and healthcare access improvements across diverse socio-economic contexts.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data sources are publicly available, with the original link being https://www.healthdata.org/research-analysis/gbd.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The title has been corrected to "Intercontinental and Regional Disparities in Cancer Burden: A Comprehensive Analysis of Trends and Projections Using 1990-2021 GBD Data with Forecasting to 2035".
Data Availability
All data generated in this study are available upon reasonable request from the authors. All data generated in this study are included in the manuscript. All data generated are accessible online.
